EMEA-002842-PIP01-20
Table of contents
Key facts
| Active substance |
Iscalimab
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0222/2021
|
| PIP number |
EMEA-002842-PIP01-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Prophylaxis of solid organ transplant rejection
|
| Route(s) of administration |
|
| Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|